JTZ 951

Drug Profile

JTZ 951

Alternative Names: JTZ-951

Latest Information Update: 01 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Japan Tobacco
  • Class Antianaemics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Anaemia

Most Recent Events

  • 01 Mar 2018 Japan Tobacco initiates enrolment in a phase III trial for Anaemia in Japan, before March 2018 (JapicCTI-183870)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Anaemia in USA (PO, Tablet)
  • 08 Nov 2017 Japan Tobacco initiates enrolment in a phase III trial for Anaemia (chronic kidney disease patients not requiring dialysis) in Japan (JapicCTI-173699)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top